ANDA 75594, held by Aesgen. Pamidronate Disodium.
As of Nov 15, 2026, ANDA 75594 (Pamidronate Disodium), held by Aesgen, was first approved by FDA on May 6, 2002, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 6, 2002 | Original application | Approved |
| Pamidronate Disodium30MG/VIAL · injectable;injection | Pamidronate Disodium | Discontinued |
| Pamidronate Disodium90MG/VIAL · injectable;injection | Pamidronate Disodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
